Name: OVID THERAPEUTICS INC (OVID) Stock
Brand: OVID THERAPEUTICS INC
Rating: 6.5 (3 reviews)

OVID Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

13 days ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

a month ago - By: Benzinga - Mentions: COCO MASI HPQ TATT ...

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

a month ago - By: Zacks Investment Research - Mentions: TWST

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

a month ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

a month ago - By: Zacks Investment Research - Mentions: MNKD

MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: ANAB

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

a month ago - By: Zacks Investment Research - Mentions: RNA

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

2 months ago - By: Zacks Investment Research - Mentions: UNH GS PSA MU ...

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

2 months ago - By: Stocktwits - Mentions: BSVO VXF

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

2 months ago - By: Benzinga - Mentions: CCCC DBVT ACIU CLPT ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

2 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

2 months ago - By: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

2 months ago - By: Ovid Therapeutics Inc.

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

4 months ago - By: Yahoo Finance

Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target

4 months ago - By: Zacks Investment Research - Mentions: OCS

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

4 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

5 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

6 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

6 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

6 months ago - By: Yahoo Finance - Mentions: TSLA NUVB

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

6 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

6 months ago - By: Ovid Therapeutics Inc.

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

7 months ago - By: Zacks Investment Research - Mentions: CVAC

OVID THERAPEUTICS INC (OVID) Stock News

OVID Latest News, Press Relases and Analysis

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

12 Health Care Stocks Moving In Friday's Pre-Market Session

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates